Vancouver’s RepliCel Signs Deals with China’s YOFOTO

Vancouver-headquartered RepliCel Life Sciences Inc., a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions, has signed agreements with China-headquartered YOFOTO Health Industry Co. Ltd. to commercialize three of RepliCel's programs in China. The deal has YOFOTO investing in RepliCel along with milestone payments, minimum program financing commitments and sales royalties in exchange for an exclusive 15-year licence to three of RepliCel products for China. YOFOTO's upfront investment will be a C$5.09-million purchase of shares at 95 cents per share and will include 20 per cent warrant coverage exercisable at 95 cents per share for a period of two years. The deal structure also includes milestone payments (of up to C$4.75 million), sales royalties, and a commitment by YOFOTO to spend a minimum of C$7 million on the RepliCel programs and associated cell processing manufacturing facility over the next five years in China.

Use 'AND' or 'OR' to refine your search.

Use quotes " " to get exact matches or remove them to get more results.